Muscular Dystrophy News1d
EMA agency continues to oppose renewing Translarna’s approval
CHMP upheld earlier opinions that Translarna is not of significant benefit to DMD due to nonsense mutations; European ...
BioWorld1d
Seaport sailing to the clinic with a $225M series B
Seaport Therapeutics Inc. has followed up its recent fundraiser with an oversubscribed $225 million series B financing that will help set it on the path to a phase IIb study of major depressive ...
Pharmabiz2d
EMA re-confirms non-renewal of conditional marketing authorisation of Duchenne muscular dystrophy medicine, Translarna
EMA re-confirms non-renewal of conditional marketing authorisation of Duchenne muscular dystrophy medicine, Translarna: Amsterdam, The Netherlands Monday, October 21, 2024, 10:00 ...
PharmTech4d
EMA Denies Authorization of Duchenne Muscular Dystrophy Treatment, Again
The agency has reconfirmed its recommendation to not give positive opinion to Translarna (ataluren) after a reexamination of the available data.
Le Lézard5d
CHMP Maintains Negative Opinion on Translarnatm Reexamination
PTC Therapeutics, Inc. announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European ...
CHMP Maintains Negative Opinion on Translarna™ Reexamination
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has maintained its negative opinion on the renewal ...
The Pharma Letter5d
BRIEF—EMA re-affirms non-renewal of masitinib and Translarna authorizations
The committee also confirmed its previous recommendation to not renew the conditional marketing authorization for PTC Therapeutics (Nasdaq: PTCT) Translarna (ataluren). All the news that moves the ...